Keratinocyte-derived circulating microRNAs in extracellular vesicles: a novel biomarker of psoriasis severity and

Young Joon Park1, Dong Chan Kim1, Soo-Jin Lee1

  • 1Department of Dermatology, Ajou University School of Medicine, Ajou University Hospital, 164, World Cup-Ro, Yeongtong-Gu, Suwon-Si, Gyeonggi-Do, 16499, South Korea.

Abstract

Insights

Plasma-derived extracellular vesicle microRNAs (EV miRNAs) show promise as psoriasis severity biomarkers. Specifically, miR-625-3p, found in keratinocytes, accurately indicates psoriasis severity and may offer a therapeutic target.

Area of Science:

  • Dermatology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Psoriasis is a chronic inflammatory skin disease with insufficient objective severity assessment tools.
  • Extracellular vesicle microRNAs (EV miRNAs) are emerging biomarkers for inflammatory conditions.
  • Investigating plasma-derived EV miRNAs for psoriasis severity correlation is crucial.

Purpose of the Study:

  • To explore plasma-derived EV miRNAs as potential biomarkers for psoriasis disease severity.
  • To identify specific EV miRNAs associated with different psoriasis severity levels.
  • To evaluate the clinical utility of EV miRNAs in assessing psoriasis.

Main Methods:

  • Extracted extracellular vesicles (EVs) from plasma of psoriasis and Behçet's disease patients.
  • Performed next-generation sequencing and qRT-PCR to analyze plasma-derived EV miRNAs.
  • Utilized in situ hybridization and cell-based assays to investigate miRNA function and signaling pathways.

Main Results:

  • Identified 19 differentially expressed EV miRNAs, validating top candidates.
  • miR-625-3p was significantly elevated in severe psoriasis patients (plasma and skin) and distinguished severity grades.
  • miR-625-3p mimic transfection increased IGF-1 signaling and cell proliferation.

Conclusions:

  • Keratinocyte-derived EV miR-625-3p is a novel, reliable biomarker for psoriasis severity.
  • This biomarker offers objective clinical assessment of psoriasis severity.
  • EV miR-625-3p represents a potential therapeutic target for psoriasis.